http://www.nejm.org/doi/full/10.1056/NEJMoa1304839
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway, M.D., Reisa Sperling, M.D., Nick C. Fox, M.D., Kaj Blennow, M.D., William Klunk, M.D., Murray Raskind, M.D., Marwan Sabbagh, M.D., Lawrence S. Honig, M.D., Ph.D., Anton P. Porsteinsson, M.D., Steven Ferris, Ph.D., Marcel Reichert, M.D., Nzeera Ketter, M.D., Bijan Nejadnik, M.D., Volkmar Guenzler, M.D., Maja Miloslavsky, Ph.D., Daniel Wang, Ph.D., Yuan Lu, M.S., Julia Lull, M.A., Iulia Cristina Tudor, Ph.D., Enchi Liu, Ph.D., Michael Grundman, M.D., M.P.H., Eric Yuen, M.D., Ronald Black, M.D., and H. Robert Brashear, M.D. for the Bapineuzumab 301 and 302 Clinical Trial Investigators
N Engl J Med 2014; 370:322-333January 23, 2014DOI: 10.1056/NEJMoa1304839
Share:
BACKGROUND
Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease.
METHODS
We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease — one involving 1121 carriers of the apolipoprotein E (APOE) e4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis. Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations.
RESULTS
There were no significant between-group differences in the primary outcomes. At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (P=0.55) with the 1.0-mg-per-kilogram dose. The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE e4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. Between-group differences were observed with respect to PIB-PET and cerebrospinal fluid phospho-tau concentrations in APOE e4 allele carriers but not in noncarriers.
CONCLUSIONS
Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE e4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.)
- Forums
- ASX - By Stock
- ATH
- nejm solanezumab
nejm solanezumab, page-2
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $313 | 104.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
51 | 77078609 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 6164594 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
51 | 77078609 | 0.002 |
23 | 117810099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 6164594 | 4 |
0.004 | 129978344 | 23 |
0.005 | 22242406 | 25 |
0.006 | 20981950 | 18 |
0.007 | 47726651 | 22 |
Last trade - 15.59pm 09/09/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |